Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JNJB34.SA
Strong BuyJohnson & Johnson · Healthcare · United States · $658.2B · Avg Vol: $135K/d
93
StockRankGet insider-trade alerts
Q
75
V
44
M
76
P/E (TTM)
31.4x
ROE
25.7%
D/E
0.6x
Dividend %
1.5%
COMPANY DESCRIPTION
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
FINANCIAL SUMMARY (BRL)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 416.4B | 443.3B | 462.3B | 490.3B | 5.6% | 509.8B | 526.4B | 566.2B | 7.5% |
| EPS (BRL) | 0.17 | 0.34 | 0.14 | 0.26 | 14.3% | — | — | — | — |
| Shares | 36.1B | 36.1B | 36.1B | 36.1B | 0.0% | 36.1B | — | — | — |
| Debt | 206.4B | 152.7B | 190.7B | 249.5B | 6.5% | 255.3B | — | — | — |
| Equity | 399.8B | 358.0B | 372.1B | 424.5B | 2.0% | — | — | — | — |
| Op CF | 110.3B | 118.6B | 126.3B | 127.7B | 5.0% | 143.7B | — | — | — |
| Inv CF | -64.4B | 4.6B | -96.8B | -122.8B | — | — | — | — | — |
| Fin CF | -46.2B | -82.4B | -16.3B | -28.8B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+10.0%
SMA 50SMA 200
Close
$17.74
RSI (14)
66.6
52W High
$18.44
From 52W High
1.0%
SCORE BREAKDOWN
Quality
75
ROIC
18.1%89.4
ROE
25.7%92.9
GP/Assets
33.5%70.8
Op. Margin
29.2%90.2
FCF/Assets
11.2%88.4
Piotroski
497.6
Int. Cover
25.9x74.0
D/E Ratio
0.58x27.3
Current Ratio
1.09x13.7
Value
44
P/E (TTM)
31.4x37.4
EV/EBITDA
18.8x35.6
P/FCF
29.6x45.6
P/B
1.5x72.1
P/S
6.7x35.4
Div Yield
1.5%38.3
Momentum
76
52W High %
96%94.7
RS 6M
17%78.2
SMA 50/200
1.10x78.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-0%37.6
FUNDAMENTALS
Market Cap
$658.2B
P/E (Forward)
—
Gross Margin
68.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JNJB34.SA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JNJB34.SA | Johnson & Johnson(you) | $658.2B | 93 | Strong Buy |
| 4AB.DE | AbbVie Inc. | $466.1B | 93 | Strong Buy |
| MRK.MX | Merck & Co., Inc. | $372.4B | 91 | Strong Buy |
| LLY.MX | Eli Lilly and Company | $1.1T | 89 | Strong Buy |
| ROP.SW | Roche Holding AG | $367.3B | 88 | Strong Buy |
| AMG.DE | Amgen Inc. | $238.5B | 93 | Strong Buy |
| NOVN.SW | Novartis AG | $299.9B | 86 | Strong Buy |
| NVON.MX | Novo Nordisk A/S | $207.3B | 95 | Strong Buy |
| PFIZ34.SA | Pfizer Inc. | $161.7B | 95 | Strong Buy |
| AZN | AstraZeneca PLC | $258.5B | 77 | Buy |
Peer medians: ROE 1.9% · P/E 24.0x · Gross margin 52.2%